Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B.63521
- Development stage
- Unknown
- Lead developer
- U.S. Army Medical Research and Development Command
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
B.63521 is a recombinant protein subunit vaccine candidate targeting the human immunodeficiency virus (HIV). It consists of the HIV-1 envelope glycoprotein gp120 from subtype B (strain 63521), designed to stimulate an immune response against HIV infection, particularly for prophylactic use in preventing acquired immunodeficiency syndrome (AIDS). The vaccine is being evaluated in combination with other antigens such as A244 and formulated with adjuvants like Army Liposome Formulation containing QS-21 saponin (ALFQ) to enhance immunogenicity. Preclinical studies have shown that vaccination with B.63521 can boost Env-specific antibody responses, including binding, avidity, and antibody-dependent cellular cytotoxicity (ADCC), especially when used in heterologous prime-boost regimens[1][4][6]. The primary indication under investigation is prevention of HIV infection.
- Other names
- HIV-1 gp120 B.63521HIV1 gp120 B.63521HIV 1 gp120 B.63521HIV b.63521/1086.C gp120
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on B.63521.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B.63521.